Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections
AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by drug-resistant bacteria.
AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo
Emblaveo was jointly developed with Pfizer. AbbVie holds U.S. and Canada commercialization rights, with Pfizer responsible for commercialization in all other areas. Last April, the European Commission granted marketing authorization for treatment of adults with complicated intra-abdominal infections,
AbbVie gets FDA approval for antibiotic treatment Emblaveo (update)
AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of aztreonam and avibactam,
BioPharma Dive
13h
Pfizer taps former Novartis exec to lead cancer drug push
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
FiercePharma
23h
Don't call it a comeback: Pfizer returns to Super Bowl with ad pledging to 'knock out' cancer
Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...
2d
on MSN
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
3d
Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
FierceBiotech
1d
Pfizer builds out oncology team with appointment of Novartis vet Jeff Legos
In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...
4d
Pfizer’s Covid Boost Overshadowed by Kennedy Threat to Vaccines
Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., ...
4d
on MSN
Pfizer beats profit estimates on heart disease drug, COVID vaccine sales
(Reuters) -Drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Thursday, boosted by cost-cutting, a ...
FierceBiotech
4d
Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates
Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...
Crain's New York
3d
Pfizer gets unexpected boost from Covid vaccine and pill
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...
3d
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
3d
Pfizer Beats Q4 Revenue, EPS Estimates
Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.
3d
on MSN
Pfizer Falls on RFK’s Progress Towards Confirmation Despite Good Earnings. Its CEO is Unbothered.
CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Super Bowl
Covid
Wall Street
Albert Bourla
Novartis
Feedback